Targeted treatment of non-small cell lung cancer

被引:0
|
作者
Scheffler, Matthias [1 ]
Michels, Sebastian [1 ]
Nogova, Lucia [1 ]
机构
[1] Univ Klinikum Koln AoR, Klin Innere Med 1, Ctr Integrierte Onkol CIO Aachen Bonn Koln Dussel, Lung Canc Grp Cologne, Kerpener Str 62, D-50937 Cologne, Germany
来源
INNERE MEDIZIN | 2022年 / 63卷 / 07期
关键词
Mutation; KRAS; EGFR; BRAF; Molecular genetic analysis; Drug resistance; neoplasm; OPEN-LABEL; ACQUIRED-RESISTANCE; INTEGRATED ANALYSIS; 1ST-LINE TREATMENT; EGFR MUTATIONS; CHEMOTHERAPY; MULTICENTER; CRIZOTINIB; PHASE-3; EFFICACY;
D O I
10.1007/s00108-022-01372-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Non-small cell lung cancer (NSCLC) has made a remarkable development in recent decades with respect to its perception. In the late 1990s it was the "problem child" as the main cause of cancer with increasing tendencies, especially in women and with a pronounced stigmatization. It is now the role model as a biologically rational targeted treatment based on molecular dependencies of the tumor with a vast improvement of the traditionally poor survival times. Molecular tumor boards have long followed the NSCLC example in the assessment of targeted treatment approaches for other tumor entities. This review article gives an overview of the current possibilities for targeted treatment of NSCLC, which nowadays are applicable for nearly one third of all patients with NSCLC.
引用
收藏
页码:700 / 708
页数:9
相关论文
共 50 条
  • [31] Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer
    Dienstmann, Rodrigo
    Martinez, Pablo
    Felip, Enriqueta
    ONCOTARGET, 2011, 2 (03) : 165 - 177
  • [32] Osimertinib for the treatment of non-small cell lung cancer
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (02) : 225 - 231
  • [33] Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists
    Bui, Kim Tam
    Cooper, Wendy A.
    Kao, Steven
    Boyer, Michael
    JOURNAL OF CLINICAL MEDICINE, 2018, 7 (08)
  • [34] Novel Therapeutic Targets in Non-small Cell Lung Cancer
    Janku, Filip
    Garrido-Laguna, Ignacio
    Petruzelka, Lubos B.
    Stewart, David J.
    Kurzrock, Razelle
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (09) : 1601 - 1612
  • [35] Understanding the treatment response and resistance to targeted therapies in non-small cell lung cancer: clinical insights and perspectives
    Zhang, Hang
    Zhang, Yingying
    Zhu, Yingying
    Dong, Tian
    Liu, Zheng
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [36] Adjuvant treatment of non-small cell lung cancer: focus on targeted therapy
    Tazza, Marco
    Metro, Giulio
    JOURNAL OF THORACIC DISEASE, 2017, 9 (10) : 4064 - 4069
  • [37] Novel targeted therapies for advanced non-small lung cancer
    Abughanimeh, Omar
    Kaur, Anahat
    El Osta, Badi
    Ganti, Apar Kishor
    SEMINARS IN ONCOLOGY, 2022, 49 (3-4) : 326 - 336
  • [38] Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context
    Le, Alexander D.
    Alzghari, Saeed K.
    Jean, Gary W.
    La-Beck, Ninh M.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2017, 13 : 223 - 236
  • [39] Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC)
    Kumarakulasinghe, Nesaretnam Barr
    van Zanwijk, Nico
    Soo, Ross A.
    RESPIROLOGY, 2015, 20 (03) : 370 - 378
  • [40] Evolution of first versus next-line targeted therapies for metastatic non-small cell lung cancer
    Waliany, Sarah
    Lin, Jessica J.
    Gainor, Justin F.
    TRENDS IN CANCER, 2025, 11 (03) : 245 - 257